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 ABSTRACT: 
 
Objectives:  To evaluate the impact of a mobile phone based, remote monitoring, 
advanced symptom management system (ASyMS©) on the incidence, severity 
and distress of six chemotherapy related symptoms (nausea, vomiting, fatigue, 
mucositis, hand foot syndrome, diarrhoea) in patients with lung, breast or 
colorectal cancer.   
 
Design:  A two group (intervention and control), by 5 time points (baseline, pre-
cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.   
Setting:  Seven clinical sites in the UK; 5 specialist cancer centres and 2 local 
district hospitals. 
 
Participants:  One hundred and twelve people with breast, lung or colorectal 
cancer receiving out patient chemotherapy. 
 
Interventions:  A mobile, phone based remote monitoring advanced symptom 
management system (ASyMS©). 
 
Main outcome measures:   Chemotherapy related morbidity of six common 
chemotherapy related symptoms (nausea, vomiting, fatigue, mucositis, hand foot 
syndrome and diarhhoea) 
 
Results:  There were significantly higher reports of fatigue in the control group 
compared to the intervention group (odds ratio 2.29, 95% CI 1.04 to 5.05, 
P=0.040) and reports of hand foot syndrome were on average lower in the 
control group (odds ratio control: intervention, 0.39, 95% CI to 0.92, P=0.031).   
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Conclusion:  The study demonstrates that ASyMS© can support the management 
of symptoms in patients with lung, breast and colorectal cancer receiving 
chemotherapy. 
 
Trial registration ISRCTN 67370244 
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INTRODUCTION  
Chemotherapy is a core component of cancer care and with projected increases 
in the incidence of cancer1 and advances in related treatments, its use is likely to 
increase considerably2-3.  However, its toxic effects put patients at risk of 
developing a number of symptoms, which if not identified in the early stages, can 
be serious and life threatening4-9.  Of concern, is that it has it has recently been 
reported that symptoms in patients with cancer are often poorly assessed and 
managed, with patients continuing to report a high burden of common 
symptoms10.   
 
Contributory factors include poor communication between patients and health 
professionals and inadequate symptom assessment11. The restructuring of 
cancer services2,12 may also be seen as a potential barrier to the delivery of 
effective symptom management.  With the implementation of new models of 
care2,3 designed to deliver services as locally as possible and the shift from in-
patient to ambulatory care, means that more patients are receiving treatments on 
an out-patient basis, resulting in them having to manage the majority of the 
associated side effects at home without direct supervision from health care 
personnel13.  
 
The use of mobile information and communications technology may be seen as a 
means by which to overcome these barriers12,14. With its increasing capabilities 
and its growing use within healthcare, many have seen it as a solution in the 
delivery of care in the home and rural setting3 and other places where medical 
personnel are not readily accessible15.  Such systems facilitate the provision of 
clear lines of 'real time' communication between patients and their health care 
providers14,16. Many of these technologies are patient centred and appear to 
complement current transitions within health care models, shifting care from the 
acute hospital setting to the home environment, with technology being used to 
rationalise and integrate services, where appropriate, based on patient need.    
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This type of technology has principally been used in the home care of patients 
with long term conditions such as chronic heart failure, asthma and diabetes17-21 
and to a lesser extent in patients with cancer22-23.  Improvements in patient 
outcomes have been reported22,24 as have reductions in the rate of 
hospitalisations, emergency room visits and increased cost savings20. 
 
The use of mobile technology appears to be well suited to the remote monitoring 
of chemotherapy related toxicity due to the high prevalence of out-patient care 
and the availability and accessibility of standardised methods of symptom 
assessment which are commonly used within clinical practice25-26.  The system 
reported here is a mobile phone based, remote monitoring, advanced symptom 
management system (ASyMS©)  which has been developed over a period of 5 
years to remotely monitor and manage chemotherapy related toxicity in patients 
with cancer22,27.   
 
Study objectives 
The primary aim of this pilot study was to investigate the viability of the trial 
design and explore any effect of the advanced symptom management system 
(ASyMS©) on the incidence, severity and distress of six chemotherapy related 
symptoms (nausea, vomiting, fatigue, mucositis, hand foot syndrome, diarrhoea) 
in patients with lung, breast or colorectal cancer.   
 
The hypotheses of the study was that the mobile phone system would provide a 
more accurate reflection of chemotherapy toxicity and provide a better means of 
monitoring chemotherapy related morbidity. 
 
METHODS 
Study design 
The study was a two group (intervention and control), by 5 time points (baseline, 
pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.   
 7
Sample 
Patients with breast, lung or colorectal cancer were selected for involvement in 
this study due to their high prevalence in the UK 41,42,43,44 and their use of 
outpatient chemotherapy services.  Patients were recruited to the study from 
March – September 2006.  They were eligible to participate in the study if they 
fulfilled the following criteria: A diagnosis of breast, lung or colorectal cancer; 
commencing a ‘new’ course of chemotherapy treatment (defined as those 
patients commencing a new chemotherapy regime irrespective of stage of 
disease or line of treatment); receiving out-patient chemotherapy; aged 18 years 
or over; written informed consent given; able to read and write English and 
deemed by members of the clinical team as being physically and psychologically 
fit to participate in the study.  Exclusion criteria were patients who are unable to 
meet the above criteria and who did not agree to give access to their case 
records.   
Recruitment  
Patients were recruited from 7 clinical sites throughout the UK (6 Scotland/1 
Engalnd).  Five of the participating sites were specialist cancer centres and the 
remaining two were local district hospitals.  The study was approved by the Fife 
& Forth Valley Medical Research Ethics Committee as the national approval 
body and within each local area. All patients provided written informed consent 
prior to their participation in the study.  
Study Randomisation 
One hundred and twelve patients were randomised using an automated 
Interactive Voice Response (IVR) telephone randomisation system at the Centre 
for Healthcare Randomised Trials Health Services Research Unit, University of 
Aberdeen.  The randomisation used a minimisation algorithm 45 based on centre 
and tumour type.  Figure 1 denotes the randomisation of participants per site.   
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 Figure 1:  Randomisation of participants per site 
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Intervention 
Patients in the intervention group used ASyMS© throughout 4 cycles of 
chemotherapy.  As ASyMS© was developed to complement standard care, 
patients using the system were also advised to follow procedures and guidelines 
related to the monitoring and reporting of chemotherapy related toxicity in their 
local area. Patients were trained on how to use the system by nurses working in 
their local area who had received training by the study team on how to use the 
ASyMS© system.   
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On days 1-14, in the morning, evening and at any time they felt unwell, patients 
randomised to the ASyMS© mobile phone group were asked to complete a 
symptom questionnaire that integrated the Common Toxicity Criteria Adverse 
Events (CTCAE) grading system26 and the Chemotherapy Symptom Assessment 
Scale25.  Symptoms assessed included nausea, vomiting, mucositis, hand-foot 
syndrome, diarrhoea and fatigue and were selected in collaboration with a team 
of cancer chemotherapy specialists and from a review of the related literature.  
This questionnaire measured the incidence, severity and distress associated with 
each symptom. The symptom questionnaire was tested for face validity by the 
project team, two patient advisory groups and by patients and health 
professionals who were involved in the earlier testing of the system39. It was 
short, simple and relevant with a standardised scoring method and demonstrated 
high levels of internal reliability (Cronbach’s alpha= 0.82). 
This symptom information was immediately sent in ‘real time’ via secure General 
Packet Radio Services (GPRS) connections to the study server. After completing 
the electronic symptom questionnaire, patients immediately received written 
feedback on the mobile phone interface, comprising of tailored self-care advice 
directly related to the severity of the symptoms they had just reported. This 
included simple instructions which patients could use to mange their symptoms 
including advice on pharmacological use, the use of distraction and relaxation 
techniques and dietary advice where appropriate.    
 
An evidence based risk assessment tool was integrated into the ASyMS© server 
software. This alerted participants’ clinicians, via a dedicated 24-hour pager 
system, of any incoming symptom reports that were considered to be clinically 
important.  An ‘amber alert’ was used to indicate to clinicians that a patient was 
experiencing toxicities at home that were not severe or life threatening but in 
which early intervention might prevent further symptom progression.  This 
included combinations of mild or moderate symptom reports which resulted in 
significant symptom burden or for symptoms which were moderate in severity but 
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had persisted over a period of 48-72 hours. A ‘red alert’ was used to indicate to 
clinicians that a patient was pyrexial and/or experiencing severe toxicities at 
home (for example severe diarrhoea). Clinicians were advised to contact patients 
within one hour of receipt of a red alert. In the event of either amber or a red 
alert, study clinicians could access secure web pages to view the patients’ 
symptom reports to assist in their clinical decision making.   
 
Control Group 
Patients in the control group received standard care following guidelines and 
procedures related to the monitoring and reporting of chemotherapy related 
toxicity in their local area. This included written information as well as verbal 
information from the nurses administering chemotherapy. 
 
Outcome measure 
In order to test the hypotheses of the study patients in both the intervention and 
control group were asked to complete a  paper version of the electronic symptom 
questionnaire at their pre-chemotherapy assessment (baseline) and before 
chemotherapy cycles 2, 3 4 and 5. This was completed by both groups at their 
clinic visit prior to administration of chemotherapy. 
 
Statistical Methods  
The study aimed to randomise a total of 150 patients in equal proportion to the 
two randomised groups (75 in each group), giving approximately 85% power at a 
5% level of significance to detect a difference in any of the six individual mean 
symptom scores between the mobile phone and the control groups of 0.5 
standard deviations (an effect size of 0.50). For the binary outcomes of 
occurrence of the symptoms, and taking the most variable case of an incidence 
of 50%, the study would have 85% power to detect a halving of this incidence to 
25%. The additional information in the serial measurements of these outcomes 
will have increased the power. Since this was to inform a larger definitive 
evaluation of the technology, which in part was investigating what the best 
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outcome would be, we did not declare any of the incidence, severity or distress 
dimensions of the six individual symptoms as being primary.    
 
All analyses presented here are intention-to-treat. Important baseline 
characteristics are summarised overall and informally compared for balance 
between randomised groups in Table 1. We compared the time to drop out using 
a log rank test, with patients last chemotherapy cycle at which they contributed 
data recorded, or if still fully participating at study end, they were censored at 
cycle 4.  
 
For the binary outcomes (did symptom occur? Y/N) and the continuous outcomes 
of severity and distress (scores 0-3) of the six individual symptoms, repeated 
measures generalised linear models with autoregressive correlation structure 
AR[1] was assumed, using an error structure appropriate for the distribution of 
the outcome – Binomial for binary outcomes and Gaussian for the assumed 
continuous outcomes 46.  The 4 on-treatment (post randomisation) cycles were 
used, and the model adjusted for age and tumour type, and the baseline version 
of the outcome being modelled and included an indicator for the randomised 
group to estimate the treatment effect. Subject was included as a random effect.  
 
The severity scores were 1 (mild), 2 (moderate) and 3 (severe) – for a patient 
who did not have the symptom, a score of zero (no symptom) was imputed. 
Likewise, for distress, the scores were 0 (not at all), 1 (a little), 2 (quite a bit), and 
3 (very much), so 0 (no symptom) was imputed if they did not have the symptom. 
A secondary analysis was conducted without imputation of these zero scores, to 
assess whether in the subgroup of patients with symptoms, there were any 
differences in severity or distress. All analyses were conducted in SAS 9.1 for 
Windows. No adjustment has been made for multiple comparisons. 
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RESULTS 
A total of 112 patients met the eligibility criteria and were recruited to the study 
over a 7 month period from March – September 2006 and participated in the 
study over 4 cycles of chemotherapy (12-16 weeks). Figures on the number of 
patients approached to take part in the study are not provided due to incomplete 
data from the participating clinical sites.   Fifty six patients were randomly 
assigned to each study arm (intervention and control).  This was 75% of the 
original target of 150, and so the study power fell to 74%, or 80% to detect a 
slightly larger effect size of 0.53. Given the feasibility nature (limited funds and 
time) of the study, there was no opportunity to either extend the recruitment 
window or recruit additional centres to achieve the full target.  
 
There was a steady decline in participants contributing data to the study, from 
100% in both groups at baseline (total n=112, n=56 in each randomised group) to 
80% (n=45) in the control group and 73% (n=41) in the intervention group (log 
rank test comparing time to drop out P=0.33). For full details see the CONSORT 
flow diagram (Figure 2). One participant withdrew before contributing any data, 3 
died before any post randomisation data could be completed, and 2 withdrew 
because they did not like the mobile phone.   
 
Demographics 
At baseline both groups were similar (Table 1) with more women than men 
recruited as breast cancer was the most common tumour type.   The Carstairs 
social deprivation score (“DepCat”) is exclusively a Scottish measure29 and is 
used as a measure of socioeconomic deprivation or affluence in different 
localities across Scotland (a score of 1 indicates the most affluent community 
and 7 the most deprived).  This was not available to the 17 patients randomised 
in England and therefore this information could not be presented for this group of 
patients. 
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Chemotherapy related toxicity 
The aim of this study was to evaluate if the mobile phone advanced symptom 
management system (ASyMS©) would provide a more accurate reflection of 
chemotherapy related toxicity and would provide a better means of monitoring 
toxicity, resulting in a decrease in chemotherapy related morbidity on six 
chemotherapy related symptoms in patients with lung, breast or colorectal 
cancer.  Two of the six symptoms measured, (fatigue and hand foot syndrome), 
showed statistical significance between the two randomised groups (Table 2).   
 
There was significantly higher reports of fatigue in the control group compared 
with the intervention group (odds ratio 2.29, 95% CI 1.04 to 5.05, P=0.040) and 
reports of hand/foot syndrome were on average lower in the control group (odds 
ratio control: intervention, 0.39, 95% CI 0.17 to 0.92, P=0.031).  
 
Exploring the severity and distress of the individual symptoms demonstrated that 
there were no significant differences between the randomised groups in the 
symptoms except for hand/foot syndrome (Table 3) for which both severity and 
distress were reported as being significantly higher in the mobile phone group 
than the control group.  Whilst not reaching statistical significance, there was a 
trend for patients in the control group to be more distressed by their fatigue 
(p=0.081) and for patients in the intervention group, to report greater severity 
(p=0.18) and distress (p=0.13) from their mucositis.  
 
DISCUSSION 
 
The results of this study indicate that the use of information and communications 
technology may be seen as a means of supporting symptom management in 
patients receiving chemotherapy. This supports earlier work which demonstrates 
the value of technology in the home care of patients with cancer or other chronic 
diseases17-21.  
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Relative to chemotherapy related toxicity, patients in the intervention group 
reported significantly lower levels of fatigue and there is a trend, albeit non-
significant, for these episodes of fatigue to be less severe and less distressing.  It 
may be postulated that patients in the intervention group reported lower levels of 
this symptom for a number of reasons.  The inclusion of descriptors of this 
symptom from the Common Toxicity Criteria26 in the patient questionnaire may 
have facilitated measurement of this subjective symptom and hence any 
subsequent intervention.  This may be supported by other studies which have 
found that health professionals do not screen for fatigue in patients with cancer 
because they are uncertain on how to assess and treat the condition31 despite 
the high prevalence of this symptom in patients with cancer32.   
 
In relation to the differences in hand foot syndrome and mucositis between both 
groups, there is either significantly more (or a trend to more) being reported in 
the mobile phone group, and for these episodes to be characterised as both 
more severe and causing more distress.  Once again this may be partly 
attributed to the inclusion of clinically meaningful descriptors within the patient 
questionnaire to facilitate assessment and management of this symptom.  The 
mobile phone may also have facilitated improved assessment of these symptoms 
which are known to be poorly assessed in routine clinical practice33-35 and it is 
hypothesised that allowing patients the opportunity to report on these symptoms 
in real time allows more accurate measurement of this toxicity which should 
result in more appropriate management.  
 
Taken together these preliminary findings suggest that ASyMS© provides a more 
accurate reflection of chemotherapy toxicity offers a better means of monitoring 
chemotherapy related toxicity and has the potential to reduce chemotherapy 
related morbidity as the significant reduction in fatigue, suggests more timely and 
effective management of debilitating symptoms.   The use of the RCT has 
allowed comparisons to be made between both groups and had also provided 
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information of sample sizes and methods of measurement which will be used in a 
later, definitive evaluation of the ASyMS© system in the remote monitoring of 
chemotherapy related toxicity. The perceptions of patients and health 
professionals using the ASyMS© system are reported elsewhere in the 
literature38, 39.  The ASyMS© system has also been developed for use in 
teenagers with cancer36 and patients with palliative care needs40 and future 
developments include its use in people with lung cancer receiving radiotherapy.     
 
Strengths and Limitations  
Whilst acknowledging limitations, this is an innovative study that pragmatically 
tests the use of technology within cancer care. The 75% recruitment rate does 
limit the effect size identified within the study and suggests the need for a larger 
trial and plans are underway begin this. The attrition of patients over the course 
of the study which was comparable for both groups suggests that use of the 
mobile phone was not a factor, however it may indicate either worsening 
symptoms or fatigue with the data collection process. Exploration of the reasons 
for attrition will be closely monitored in future studies. 
 
In relation to the completion of the symptom questionnaire, patients within the 
intervention arm were reporting the symptoms twice daily within the mobile 
phone and so may have reported their symptoms differently on the paper based 
questionnaire following each cycle of chemotherapy as they were more familiar 
with the questions. Also, as the same questionnaire was used as an intervention 
on the mobile phone and as an outcome measure, the differences observed 
between the intervention and control groups may be due to the learning effect of 
the intervention group in completing the same questionnaire.  Furthermore, whilst 
we assessed the impact of the ASyMS© system on chemotherapy related toxicity, 
we did not measure additional parameters such as quality of life or the impact of 
the system on self care behaviour, which are pertinent issues relative to the use 
of such technology in this patient group and its utility within clinical practice.  In 
addition use of the DepCat” an exclusively Scottish measure29 limited analysis of 
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the total sample and this will be rectified in future studies. Future work will 
consider all these issues and will include an economic evaluation to assess cost 
benefit of such technology within cancer care.  
 
CONCLUSIONS 
The study demonstrates that the ASyMS© system can support the management 
of symptoms in patients with breast, lung and colorectal cancer receiving 
chemotherapy. It has demonstrated that the ASyMS© system could provide a 
more accurate reflection of chemotherapy related toxicity and could provide a 
better means of monitoring toxicity in clinical practice with the potential to 
decrease chemotherapy related morbidity. In addition it offers a systematic 
approach to symptom assessment which in the future could afford comparison of 
chemotherapy related toxicity and facilitate a more accurate picture of the real 
time morbidity experience of patients receiving chemotherapy. 
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Table 1: Baseline characteristics for all participants and for patients assigned to the intervention and control groups.  DEPCAT scores reported 
only for Scottish site patients.  Values are in numbers (percentages) unless stated otherwise. 
Characteristics All Patients  
(n=112) 
Intervention  
Group (n=56) 
Control  
Group (n=56) 
Mean age years 
(Std.Dev) 
56.0  
(10.5) 
55.1 
(10.6) 
56.9 
(10.5) 
Sex  n (%) 
Male  
Female 
 
26 (23.2) 
86 (76.8) 
 
15 (26.8) 
41 (73.2) 
 
11 (19.6) 
45 (80.4) 
Tumour type n (%) 
Breast 
Lung 
Colorectal 
 
70 (62.5) 
26 (23.2) 
16 (14.3) 
 
34 (60.7) 
13 (23.2) 
9 (16.1) 
 
36 (64.3) 
13 (23.2) 
7 (12.5) 
*Dep cat score n (%) 
1 
2 
3 
4 
5 
6 
(n=95) 
  9 (9.5) 
28 (29.5) 
27 (28.4) 
11 (11.6) 
11 (11.6) 
  9 (9.5) 
(n=47) 
5 (10.6) 
16 (34.0) 
13 (27.7) 
6 (12.8) 
5 (10.6) 
2 (4.3) 
(n=48) 
4 (8.3) 
12 (25.0) 
14 (29.2) 
5 (10.4) 
6 (12.5) 
7 (14.6) 
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Chemotherapy regime n (%) 
 
FEC 
AC 
Carbo-gem 
Cis-gem 
Cis-etoposide 
CAPOX 
Capecitabine 
Taxotere 
Other 
 
 
32 (28) 
23 (20) 
8   (7) 
6   (5) 
5   (5) 
8   (7) 
3   (3) 
4    (4) 
23 (21) 
 
 
 
15 (27) 
12 (21) 
5   (9) 
3   (5) 
2   (4) 
4   (7) 
2 (2) 
3 (5) 
10 (16) 
 
 
 
17 (30) 
11 (20) 
3 (5) 
3 (5) 
3 (5) 
4 (7) 
1 (2) 
1 (2) 
13 (25) 
Table 2 :Estimated intervention effects, non-mobile compared with mobile randomised groups. Primary outcome of 
symptom scores, and the occurrence of the 6 symptoms that are components of the total symptom score.  
Measure Non-mobile 
group** 
Mobile 
group** 
Non-mobile 
vs. mobile 
estimated 
difference* 
95% 
confidence 
interval 
P-value 
Vomiting 21.9% 20.3% 1.23 0.57 to 2.68 0.60 
Nausea 61.1% 53.9% 1.55 0.77 to 3.12 0.22 
Diarrhoea 30.2% 33.0% 0.97 0.51 to 1.82 0.91 
Hand/foot 
syndrome 
12.2% 24.0% 0.39 0.17 to 0.92 0.031 
Sore Mouth or 
Throat 
42.1% 53.3% 0.78 0.41 to 1.48 0.44 
Fatigue 81.3% 67.3% 2.29 1.04 to 5.05 0.040 
 
* All odds ratios (non-mobile:mobile) 
** The average proportion of subjects with the attribute over the 4 post randomisation cycles. 
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Table 3 : Severity and distress of the six symptoms. The data shown are the raw mean(SD), while the estimated 
difference, 95% confidence interval and P-value are from the adjusted model.     
 
Measure Non-mobile 
group: mean 
(SD) 
Mobile group 
: mean (SD) 
Non-mobile 
vs.mobile 
estimated 
difference* 
95% 
confidence 
interval 
P-value 
Severity      
Vomiting 0.50(0.81) 0.51(0.93) 0.04 -0.29 to 0.38 0.80 
Nausea 1.43(1.08) 1.23(1.19) 0.25 -0.16 to 0.67 0.23 
Diarrhoea 0.56(0.70) 0.60(0.76) -0.06 -0.32 to 0.20 0.64 
Hand/foot syndrome 0.22(0.49) 0.46(0.64) -0.27 -0.52 to -0.02 0.033 
Sore Mouth/Throat 0.78(0.80) 1.05(0.89) -0.22 -0.54 to 0.10 0.18 
Fatigue 1.82(1.09) 1.54(1.11) 0.24 -0.14 to 0.63 0.21 
Distress      
Vomiting 0.32(0.51) 0.35(0.65) -0.02 -0.24 to 0.20 0.87 
Nausea 1.06(0.87) 0.93(0.91) 0.13 -0.18 to 0.45 0.40 
Diarrhoea 0.40(0.51) 0.40(0.47) 0.03 -0.14 to 0.20 0.77 
Hand/foot syndrome 0.16(0.34) 0.30(0.45) -0.17 -0.33 to -0.02 0.028 
Sore Mouth/Throat 0.55(0.54) 0.74(0.62) -0.17 -0.39 to 0.05 0.13 
Fatigue 1.52(0.88) 1.24(0.91) 0.28 -0.03 to 0.59 0.081 
 
